UNITY Biotechnology

OverviewSuggest Edit

Unity Biotechnology designs therapeutics that prevent various diseases of aging. The company focuses on clearing senescent cells and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.
TypePublic
Founded2009
HQSouth San Francisco, CA, US
Websiteunitybiotechnology.com
Employee Ratings3.4

Latest Updates

Employees (est.) (May 2017)7
Share Price (Jan 2021)$6
Cybersecurity ratingAMore

Key People/Management at UNITY Biotechnology

Keith R. Leonard

Keith R. Leonard

Chairman
Nathaniel David

Nathaniel David

Co-Founder and President, Director
Lynne Sullivan

Lynne Sullivan

Chief Financial Officer
Jamie Dananberg

Jamie Dananberg

Chief Medical Officer
Dan Marquess

Dan Marquess

Chief Scientific Officer
Susan Lundeen

Susan Lundeen

Senior Vice President of People
Show more

UNITY Biotechnology Office Locations

UNITY Biotechnology has offices in South San Francisco and Brisbane
South San Francisco, CA, US (HQ)
285 E Grand Ave
Brisbane, CA, US
3280 Bayshore Blvd
Show all (2)

UNITY Biotechnology Financials and Metrics

UNITY Biotechnology Revenue

USD

Net income (Q3, 2020)

(27.6m)

EBIT (Q3, 2020)

(24.6m)

Market capitalization (11-Jan-2021)

318.0m

Closing stock price (11-Jan-2021)

6.0

Cash (30-Sept-2020)

48.6m

EV

293.7m
UNITY Biotechnology's current market capitalization is $318 m.
Annual
USDFY, 2018FY, 2019

General and administrative expense

16.0m20.0m

R&D expense

58.9m71.0m

Operating expense total

74.9m91.0m

EBIT

(79.5m)(89.7m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

General and administrative expense

3.5m3.8m4.4m4.5m5.0m5.7m6.0m6.3m6.5m

R&D expense

13.0m15.2m14.4m16.5m18.5m17.8m19.3m16.1m18.8m

Operating expense total

16.5m19.0m18.7m21.0m23.4m23.5m25.2m22.4m25.4m

EBIT

(16.5m)(20.8m)(19.4m)(19.7m)(24.5m)(22.4m)(27.2m)(23.3m)(24.6m)
Annual
USDFY, 2018FY, 2019

Cash

15.4m37.5m

Prepaid Expenses

1.8m2.0m

Current Assets

173.0m129.5m

PP&E

6.2m16.6m
Quarterly
Annual
USDFY, 2018FY, 2019

Net Income

(76.4m)(82.2m)

Depreciation and Amortization

2.2m2.7m

Accounts Payable

2.2m(227.0k)

Cash From Operating Activities

(56.6m)(72.4m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(16.1m)(36.1m)(54.5m)(18.8m)(42.4m)(64.1m)(28.0m)(46.7m)

Depreciation and Amortization

502.0k1.0m1.6m637.0k1.3m1.9m903.0k1.8m2.6m

Accounts Payable

1.8m(633.0k)91.0k(776.0k)391.0k(331.0k)(1.3m)(1.3m)(966.0k)

Cash From Operating Activities

(11.9m)(29.9m)(43.8m)(20.6m)(39.9m)(56.7m)(25.1m)(44.4m)(61.6m)
USDQ1, 2018

Financial Leverage

-1.5 x
Show all financial metrics

UNITY Biotechnology Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

UNITY Biotechnology Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

UNITY Biotechnology Online and Social Media Presence

Embed Graph

UNITY Biotechnology Company Culture

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    100/100

Learn more on Comparably

UNITY Biotechnology News and Updates

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that from December 1, 2020 through December 15, 2020, the Board of Directors…

UNITY Biotechnology Announces Appointment of Clinical Development and Industry Veteran Gilmore O’Neill, M.B., to the Board of Directors

Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY’s Board

UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2020.

UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology

- Corporate restructuring to extend cash runway through mid-2022 and key milestones -

Thinking about buying stock in Immatics NV, Biocept Inc, LMP Automotive, Unity Biotechnology, or Barrick Gold Corp?

NEW YORK, Aug. 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMTX, BIOC, LMPX, UBX, and GOLD. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

UNITY Biotechnology, Inc. Reports Second Quarter 2020 Financial Results and Clinical Program Updates

SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the second quarter ended June…
Show more

UNITY Biotechnology Blogs

UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema

SAN FRANCISCO , Oct. 12, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that the first patient has been dosed in a Phase 1 study of UBX1325

UNITY Biotechnology to Participate in Upcoming September Investor Conferences

SAN FRANCISCO , Sept. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the

UNITY Biotechnology Announces 12-week data from UBX0101 Phase 2 Clinical Study in Patients with Painful Osteoarthritis of the Knee

UBX0101 failed to meet 12-week primary endpoint Guidance for UNITY’s Bcl-xL inhibitor UBX1325 in retinal disease remains unchanged UNITY to focus senescence programs on ophthalmologic and neurologic diseases in near-term UNITY to hold investor and analyst conference call today, Monday, August 17,

UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital

UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital Content Import Tue, 08/04/2020 - 16:07 UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital August 4, 2020 at 4:05 PM EDT This release is a backfill from a News Wire …

UPDATE – UNITY Biotechnology, Inc. to Announce Second Quarter 2020 Financial Results

SAN FRANCISCO , July 29, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the second quarter ended

UNITY Biotechnology, Inc. to Announce Second Quarter 2020 Financial Results

SAN FRANCISCO , July 24, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the second quarter ended
Show more

UNITY Biotechnology Frequently Asked Questions

  • When was UNITY Biotechnology founded?

    UNITY Biotechnology was founded in 2009.

  • Who are UNITY Biotechnology key executives?

    UNITY Biotechnology's key executives are Keith R. Leonard, Nathaniel David and Lynne Sullivan.

  • How many employees does UNITY Biotechnology have?

    UNITY Biotechnology has 7 employees.

  • Who are UNITY Biotechnology competitors?

    Competitors of UNITY Biotechnology include Epirium Bio, Urovant Sciences and Abiogen Pharma.

  • Where is UNITY Biotechnology headquarters?

    UNITY Biotechnology headquarters is located at 285 E Grand Ave, South San Francisco.

  • Where are UNITY Biotechnology offices?

    UNITY Biotechnology has offices in South San Francisco and Brisbane.

  • How many offices does UNITY Biotechnology have?

    UNITY Biotechnology has 2 offices.